Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
04 août 2022 16h05 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
27 juin 2022 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
13 juin 2022 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
25 févr. 2022 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
12 nov. 2021 08h01 HE
|
Akero Therapeutics
Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological...
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
19 oct. 2021 16h15 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
05 oct. 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
07 sept. 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
13 août 2021 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...